iShares Biotechnology ETF
899 hedge funds and large institutions have $5.97B invested in iShares Biotechnology ETF in 2022 Q4 according to their latest regulatory filings, with 140 funds opening new positions, 257 increasing their positions, 288 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
3.64% more ownership
Funds ownership: 61.62% → 65.26% (+3.6%)
11% less repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 288
36% less call options, than puts
Call options by funds: $325M | Put options by funds: $511M
Holders
899
Holding in Top 10
22
Calls
$325M
Puts
$511M
Top Buyers
| 1 | +$149M | |
| 2 | +$137M | |
| 3 | +$85.8M | |
| 4 |
Goldman Sachs
New York
|
+$72.3M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$51.7M |
Top Sellers
| 1 | -$77.3M | |
| 2 | -$58.8M | |
| 3 | -$50.3M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$49.4M |
| 5 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
-$20.8M |